Renalytix PLC (RENXF) 주가 예측

Renalytix Plc engages in the manufacturing of medical devices and equipment. The firm is engaged in a field of bioprognosis for kidney health. The firm has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. KidneyIntelX, is a vitro diagnostic platform, employs a proprietary algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record or EHR, systems, to generate a patient risk score. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.